TrialFrontiers in immunology2024

The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis.

Sheng-Xiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.